Study of JMKX003948 Ophthalmic Suspension in Healthy Participants

Официальное название

A Randomized, Double-blind, Placebo-controlled Phase 1 Study of JMKX003948 Ophthalmic Suspension to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Dose(s) in Healthy Participants

Обзор

The study is a randomized, double-blind, placebo-controlled, phase 1 study of JMKX003948 Ophthalmic Suspension to evaluate the safety, tolerability and PK of single and multiple ascending doses in healthy participants. Participant will be randomized to receive either JMKX003948 Ophthalmic Suspension (1%, 2%, 3% or 5%) or matching placebo (JMKX003948 Ophthalmic Suspension: placebo= 6: 2, N=8 per cohort). Five cohorts (Cohort 1-5) are planned. Cohorts could also de-escalate to a lower concentration if current formulation was not tolerated (Cohort 1b, 2b and 3b). In case of de-escalation, Cohort 1b and 2b will continue to escalate to Cohort 1c and Cohort 2c, respectively. Participants will be admitted to the site on Day -1 after screening (up to 28 days), and remain domiciled until Day 14 for Cohort 1-4, Day 8 for other cohorts.

Вмешательства

• Препарат JMKX003948 Ophthalmic Suspension
  JMKX003948 Ophthalmic Suspension with formulation 1% (15 mg/1.5 mL), 2% (30 mg/1.5 mL), 3% (45 mg/1.5 mL), 5% (75 mg/1.5 mL)
• Препарат Placebo
  JMKX003948 Ophthalmic Suspension placebo

Первичные конечные точки

• Adverse events (AEs) [Срок оценки: From Day1 to up to Day14]
• Number of Participants With abnormal Ophthalmic examination [Срок оценки: From Day1 to up to Day14]

Вторичные конечные точки (4)

• Maximum concentration (Cmax) [Срок оценки: From Day1 to up to Day14]
• Area under the concentration-time curve [Срок оценки: From Day1 to up to Day14]
• Time to Cmax (Tmax) [Срок оценки: From Day1 to up to Day14]
• Elimination half-life (t1/2) [Срок оценки: From Day1 to up to Day14]

Критерии участия

Критерии включения

• Healthy adult males and/or females, 18 to 45 years of age (inclusive) at the date of signed consent form.
• Body mass index (BMI) greater than or equal to 18 and less than 32 (kg/m2) and a minimum body weight of 45 kg.
• Able to participate and comply with all study procedures and restrictions, and willing to provide written informed consent to participate in the study.
• Women of child-bearing potential and sexually active males willing to use highly effective methods of contraception from screening until 3 months after last dose of study drug. In addition, participants must not donate sperm/egg for the time period specified above.

Критерии исключения

• History of disease of ocular surface, fundus, central nervous system, psychiatric and psychological condition, cardiovascular system, kidney, liver, digestive system, respiratory system, or metabolic/endocrine system, or other disease that in the opinion of the Investigator (or medically qualified designee) may make participation unsafe for the participant or interfere with study evaluations.
• Any abnormal examination with clinical significance may interfere with study evaluations in opinion of the Investigator (or medically qualified designee).
• History of eye trauma or surgery including LASIK/LASEK.
• Any corrected visual acuity < 20/20, or intraocular pressure ≥ 21 mmHg.
• Clinically significant abnormalities on ophthalmic examination that would hinder the assessment of the eye or data collection at the discretion of the Investigator and/or ophthalmologist (or medically qualified designee).

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Распределение

Рандомизированное

Модель

Последовательный дизайн

Маскирование

Четверное слепое

Основная цель

Лечение

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Идентификаторы

NCT: NCT06832657 · JMKX003948-101

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗